Zheng Y, Xiu W, Lin Y, et al. - In preventing bronchopulmonary dysplasia (BPD; one of the most common complications in premature infants), researchers analyzed the long-term impacts of the intratracheal administration of corticosteroids (IAC). In order to identify randomized controlled trials (RCTs) assessing the long-term impacts of IAC for the prevention of BPD in premature infants, they searched EMBASE, MEDLINE, the Cochrane Library, Web of Science, CINAHL, Clinicaltrials.gov, the ISRCTN registry, and gray literature. Further assessment was eligible for five RCTs (n = 1,515). The meta-analysis disclosed that there was no significant difference between the IAC group and the control group between the incidence of neurodevelopmental impairment. No significant reduction was found in long-term mortality or the incidence of rehospitalization. There were no significant differences in height, weight and head circumference between the IAC group and the control group at 18 to 36 months of postmenstrual age. The research indicates that there are no significant long-term advantages or negative results in IAC in preterm infants. However, to verify IAC's pharmacokinetics and long-term impacts, well-designed tests and studies involving large sample sizes are required before routine use.